Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota

NAActive, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

July 15, 2021

Study Completion Date

February 28, 2031

Conditions
Alcoholic Liver DiseaseLiver Cirrhosis, AlcoholicProbioticsLiver Fibrosis
Interventions
DIETARY_SUPPLEMENT

Profermin Plus, FSMP, probiotics

"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."

DIETARY_SUPPLEMENT

Fresubin, dietary supplement

Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.

Trial Locations (2)

5000

FLASH - Centre of Liver Research, Odense

Odense University Hospital, Odense

All Listed Sponsors
collaborator

Region of Southern Denmark

OTHER

collaborator

Odense Patient Data Explorative Network

OTHER

collaborator

University of Southern Denmark

OTHER

collaborator

Nordisk Rebalance A/S

INDUSTRY

lead

Odense University Hospital

OTHER